Anti-D Immunoglobulin Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Anti-D Immunoglobulin Market Between 2025 And 2029?

The anti-D immunoglobulin market has experienced significant expansion in recent years. It is anticipated to increase from $2.42 billion in 2024 to $2.59 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.9%. The growth observed in the past can be ascribed to an uptick in awareness regarding rhesus incompatibility risks, the expansion of national immunization programs, the establishment of maternal and neonatal health policies, an increase in global birth rates, and a rise in blood transfusion procedures.

The anti-D immunoglobulin market is projected to experience robust expansion over the coming years, forecast to reach a value of $3.34 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period stems from factors such as increasing demand for antenatal and perinatal care, a heightened focus on maternal health in low- and middle-income countries, greater investments in healthcare infrastructure, the expansion of universal health coverage initiatives, and supportive regulatory frameworks for immunoglobulin therapies. Key trends expected during this period involve progress in plasma fractionation technology, the emergence of recombinant antibody alternatives, enhanced automation in immunoglobulin production, the implementation of high-purity formulation techniques, and the incorporation of cold chain monitoring systems.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25694&type=smp

Which Drivers Are Impacting The Anti-D Immunoglobulin Market?

Elevated birth rates are projected to fuel the expansion of the anti-D immunoglobulin market moving forward. These rates, defined as the yearly count of live births per 1,000 individuals in a population, are rising because of inadequate access to educational resources and family planning initiatives, leading to increased fertility and larger family sizes. Anti-D immunoglobulin contributes to healthier birth outcomes by preventing Rh incompatibility during pregnancy, thereby lowering the risk of hemolytic disease in newborns and fostering better results in subsequent pregnancies. For example, the Centers for Disease Control and Prevention, a US government body, reported 3,622,673 births in 2024 as of April 2025, marking a 1% rise from the prior year. Consequently, the rising birth rates are a key factor propelling the anti-D immunoglobulin market’s growth. The growth of the anti-D immunoglobulin market is anticipated to be spurred by the ongoing expansion of healthcare infrastructure. This infrastructure encompasses the facilities, equipment, personnel, and support systems vital for providing health services to a population. Its expansion is driven by the increasing global populace, which creates a greater need for medical care and thus requires the establishment of more hospitals, clinics, and associated resources. Enhanced healthcare infrastructure improves accessibility to maternal care, facilitating more effective screening and prompt administration of anti-D immunoglobulin to avert hemolytic disease in newborns. For instance, in May 2023, the Department of Health and Social Care, a UK government body, unveiled plans to invest over $27 billion (£20 billion) in constructing new hospital facilities. Under the New Hospital Programme, two hospitals have been completed, five are under construction, and more than 20 are slated for commencement or completion by the close of the subsequent year. Consequently, the expanding healthcare infrastructure is significantly contributing to the anti-D immunoglobulin market’s growth.

How Is The Anti-D Immunoglobulin Market Classified Into Different Segments?

The anti-d immunoglobulin market covered in this report is segmented –

1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel

3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications

4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories

Subsegments:

1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials

2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials

Which Ongoing Trends Are Expected To Shape The Anti-D Immunoglobulin Market Outlook?

Major companies operating in the anti-D immunoglobulin market are prioritizing the development of innovative solutions, such as recombinant anti-D immunoglobulin, to broaden access to safe and reliable prophylaxis for Rh-negative pregnant individuals and enhance maternal outcomes. A recombinant anti-D immunoglobulin is a lab-engineered monoclonal antibody designed to prevent Rh incompatibility in Rh-negative individuals, serving as an alternative to plasma-derived anti-D therapies with improved consistency, safety, and scalability. For instance, in January 2022, Bharat Serums and Vaccines (BSV), an India-based biopharmaceutical company, launched the world’s first marketed recombinant anti-Rho (D) immunoglobulin. This product introduces a scientifically advanced approach to Rh prophylaxis through recombinant technology, which boosts its reliability and minimizes variability associated with plasma-derived alternatives. Its availability is particularly significant in regions with high numbers of Rh-negative pregnancies, where it can enhance preventive care and reduce the risk of hemolytic disease in newborns.

Who Are The Core Companies Influencing The Anti-D Immunoglobulin Market Landscape?

Major companies operating in the anti-d immunoglobulin market are Merck Group, Bayer AG, CSL Behring, Baxter International Inc., Intas Pharmaceuticals Ltd., Octapharma AG, Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kedrion Biopharma Inc., Biotest AG, Sanquin, Taj Pharmaceuticals Limited, Kamada Pharmaceuticals, Bharat Serums and Vaccines Limited, Saol Therapeutics Inc., Aetos Pharma Private Limited, Avin Darou, PV Pharma Healthcare Pvt. Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Ocean Pharmacoat Pvt. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/anti-d-immunoglobulin-global-market-report

What Are The Key Regional Factors Influencing The Anti-D Immunoglobulin Market Growth?

North America was the largest region in the anti-D immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Anti-D Immunoglobulin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25694&type=smp

Browse Through More Reports Similar to the Global Anti-D Immunoglobulin Market 2025, By The Business Research Company

Immunoglobulins Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Intravenous Immunoglobulin Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Immunoassay Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795